Literature DB >> 25359475

Linear B-cell epitope mapping of MAPK3 and MAPK4 from Leishmania braziliensis: implications for the serodiagnosis of human and canine leishmaniasis.

Daniel Menezes-Souza1, Tiago Antônio de Oliveira Mendes, Ana Carolina de Araújo Leão, Matheus de Souza Gomes, Ricardo Toshio Fujiwara, Daniella Castanheira Bartholomeu.   

Abstract

The correct and early identification of humans and dogs infected with Leishmania are key steps in the control of leishmaniasis. Additionally, a method with high sensitivity and specificity at low cost that allows the screening of a large number of samples would be extremely valuable. In this study, we analyzed the potential of mitogen-activated protein kinase 3 (MAPK3) and mitogen-activated protein kinase 4 (MAPK4) proteins from Leishmania braziliensis to serve as antigen candidates for the serodiagnosis of human visceral and tegumentary leishmaniasis, as well as canine visceral disease. Moreover, we mapped linear B-cell epitopes in these proteins and selected those epitopes with sequences that were divergent in the corresponding orthologs in Homo sapiens, in Canis familiaris, and in Trypanosoma cruzi. We compared the performance of these peptides with the recombinant protein using ELISA. Both MAPK3 and MAPK4 recombinant proteins showed better specificity in the immunodiagnosis of human and canine leishmaniasis than soluble parasite antigens and the EIE-leishmaniose-visceral-canina-bio-manguinhos (EIE-LVC) kit. Furthermore, the performance of this serodiagnosis assay was improved using synthetic peptides corresponding to B-cell epitopes derived from both proteins.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25359475     DOI: 10.1007/s00253-014-6168-7

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  11 in total

1.  Evaluation of a hypothetical protein for serodiagnosis and as a potential marker for post-treatment serological evaluation of tegumentary leishmaniasis patients.

Authors:  Mariana Pedrosa Lima; Lourena Emanuele Costa; Mariana Costa Duarte; Daniel Menezes-Souza; Beatriz Cristina Silveira Salles; Thaís Teodoro de Oliveira Santos; Fernanda Fonseca Ramos; Miguel Angel Chávez-Fumagalli; Amanda Christine Silva Kursancew; Roberta Passamani Ambrósio; Bruno Mendes Roatt; Ricardo Andrez Machado-de-Ávila; Denise Utsch Gonçalves; Eduardo Antonio Ferraz Coelho
Journal:  Parasitol Res       Date:  2017-02-01       Impact factor: 2.289

2.  Proteins Selected in Leishmania (Viannia) braziliensis by an Immunoproteomic Approach with Potential Serodiagnosis Applications for Tegumentary Leishmaniasis.

Authors:  Mariana C Duarte; Daniel C Pimenta; Daniel Menezes-Souza; Rubens D M Magalhães; João L C P Diniz; Lourena E Costa; Miguel A Chávez-Fumagalli; Paula S Lage; Daniela C Bartholomeu; Maria Julia M Alves; Ana Paula Fernandes; Manuel Soto; Carlos A P Tavares; Denise U Gonçalves; Manoel O C Rocha; Eduardo A F Coelho
Journal:  Clin Vaccine Immunol       Date:  2015-09-16

Review 3.  A new Leishmania-specific hypothetical protein and its non-described specific B cell conformational epitope applied in the serodiagnosis of canine visceral leishmaniasis.

Authors:  Daniela P Lage; Vívian T Martins; Mariana C Duarte; Lourena E Costa; Esther Garde; Laura M Dimer; Amanda C S Kursancew; Miguel A Chávez-Fumagalli; Danielle F de Magalhães-Soares; Daniel Menezes-Souza; Bruno M Roatt; Ricardo A Machado-de-Ávila; Manuel Soto; Carlos A P Tavares; Eduardo A F Coelho
Journal:  Parasitol Res       Date:  2016-01-19       Impact factor: 2.289

4.  Development of an immunogen containing CD4+/CD8+ T-cell epitopes for the prophylaxis of tegumentary leishmaniasis.

Authors:  Isabela de Andrade Ferraz; Ana Maria Ravena Severino Carvalho; Rory Cristiane Fortes de Brito; Bruno Mendes Roatt; Vívian Tamietti Martins; Daniela Pagliara Lage; Luiza Dos Reis Cruz; Fernanda Alvarenga Cardoso Medeiros; Denise Utsch Gonçalves; Manoel Otávio da Costa Rocha; Eduardo Antonio Ferraz Coelho; Tiago Antônio de Oliveira Mendes; Mariana Costa Duarte; Daniel Menezes-Souza
Journal:  Appl Microbiol Biotechnol       Date:  2022-06-27       Impact factor: 5.560

5.  Immunodiagnosis of canine visceral leishmaniasis using mimotope peptides selected from phage displayed combinatorial libraries.

Authors:  Christina Monerat Toledo-Machado; Ricardo Andrez Machado de Avila; Christophe NGuyen; Claude Granier; Lilian Lacerda Bueno; Claudia Martins Carneiro; Daniel Menezes-Souza; Rubens Antonio Carneiro; Carlos Chávez-Olórtegui; Ricardo Toshio Fujiwara
Journal:  Biomed Res Int       Date:  2015-01-29       Impact factor: 3.411

6.  Development of a Peptide ELISA for the Diagnosis of Aleutian Mink Disease.

Authors:  Fanshu Ma; Lei Zhang; Yang Wang; Rongguang Lu; Bo Hu; Shuang Lv; Xianghong Xue; Xintong Li; Mingyu Ling; Sining Fan; Hailing Zhang; Xijun Yan
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

7.  Synthetic Peptides as Potential Antigens for Cutaneous Leishmaniosis Diagnosis.

Authors:  Juliana Seger Link; Silvana Maria Alban; Carlos Ricardo Soccol; Gilberto Vinicius Melo Pereira; Vanete Thomaz Soccol
Journal:  J Immunol Res       Date:  2017-03-07       Impact factor: 4.818

8.  New antigens for the serological diagnosis of human visceral leishmaniasis identified by immunogenomic screening.

Authors:  Ana Maria Ravena Severino Carvalho; Tiago Antônio de Oliveira Mendes; Eduardo Antonio Ferraz Coelho; Mariana Costa Duarte; Daniel Menezes-Souza
Journal:  PLoS One       Date:  2018-12-20       Impact factor: 3.240

9.  Systematic review on antigens for serodiagnosis of visceral leishmaniasis, with a focus on East Africa.

Authors:  Vera Kühne; Zahra Rezaei; Paul Pitzinger; Philippe Büscher
Journal:  PLoS Negl Trop Dis       Date:  2019-08-15

10.  Biochemical characterization and chemical validation of Leishmania MAP Kinase-3 as a potential drug target.

Authors:  Shweta Raj; Gundappa Saha; Santanu Sasidharan; Vikash Kumar Dubey; Prakash Saudagar
Journal:  Sci Rep       Date:  2019-11-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.